{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:05:32Z","timestamp":1790399132696,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.berh.2021.101672","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T01:25:48Z","timestamp":1616203548000},"page":"101672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Martin","family":"Aringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2021.101672_bib1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"Gabrielli","year":"2009","journal-title":"Scleroderma. N.Engl.J Med."},{"key":"10.1016\/j.berh.2021.101672_bib2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2021.101672_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2021.101672_bib4","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib5","doi-asserted-by":"crossref","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","article-title":"Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2021.101672_bib6","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2021.101672_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2021.101672_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.berh.2021.101672_bib9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00296-017-3826-y","article-title":"Determinants of mortality in systemic sclerosis: a focused review","volume":"38","author":"Poudel","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2021.101672_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00309-2019","article-title":"Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA","volume":"6","author":"Ratanawatkul","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.berh.2021.101672_bib11","doi-asserted-by":"crossref","first-page":"101671","DOI":"10.1016\/j.berh.2021.101671","article-title":"Antifibrotics in systemic sclerosis","volume":"35","author":"Martin-Lopez","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780340803","article-title":"Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only","volume":"34","author":"Steinberg","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2021.101672_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A\u00a0randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib15","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2021.101672_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.berh.2021.101672_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101672_bib18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"Contreras","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2021.101672_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2021.101672_bib20","first-page":"1325","article-title":"A\u00a0pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease","volume":"25","author":"V\u00e1rai","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s100670050138","article-title":"Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma","volume":"18","author":"Davas","year":"1999","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib22","first-page":"731","article-title":"Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis","volume":"29","author":"Giacomelli","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03009740510026896","article-title":"Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease","volume":"35","author":"Valentini","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib24","first-page":"293","article-title":"Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase","volume":"25","author":"Air\u00f2","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib25","first-page":"2371","article-title":"Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function","volume":"29","author":"Griffiths","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl 125","key":"10.1016\/j.berh.2021.101672_bib26","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials","volume":"38","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14397595.2019.1640343","article-title":"Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: a Bayesian network analysis","volume":"30","author":"Zheng","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semarthrit.2014.09.003","article-title":"Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders","volume":"44","author":"Iudici","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101672_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.berh.2021.101672_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.berh.2021.101672_bib32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","article-title":"Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease","volume":"29","author":"Koutroumpas","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"Sime\u00f3n-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"Suppl 100","key":"10.1016\/j.berh.2021.101672_bib34","first-page":"170","article-title":"Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study","volume":"34","author":"Owen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.berh.2021.101672_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10067-012-2155-5","article-title":"Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis","volume":"32","author":"Henes","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.berh.2021.101672_bib38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib40","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03009742.2016.1231341","article-title":"Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Ebata","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2021.101672_bib43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101672_bib44","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101672_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A\u00a0multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib48","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101672_bib49","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101672_bib50","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101672_bib51","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.berh.2021.101672_bib52","article-title":"Safety and efficacy of sucutaneous tocilizumab in systemic sclerosis: results form the open-label period of a phase 3 trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib53","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis","volume":"47","author":"de Vries-Bouwstra","year":"2020","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101672_bib55","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101672_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib57","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101672_bib58","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2021.101672_bib59","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:54Z","timestamp":1761499254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521694221000140"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101672","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101672"}}